N-Terminal domain antiandrogen

N-Terminal domain antiandrogen
Drug class
EPI-001, the first major N-terminal domain AR antagonist to be developed.
Class identifiers
Synonyms	N-Terminal domain AR antagonists; AR NTD antagonists
Use	Prostate cancer
Biological target	Androgen receptor
Legal status
In Wikidata

N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.

See also

• Androgen deprivation therapy
• 5N-Bicalutamide

References

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e

This page was last edited on 11 January 2019, at 11:43